OrthoPediatrics (NASDAQ:KIDS) CEO David Bailey Sells 19,535 Shares

OrthoPediatrics Corp. (NASDAQ:KIDS) CEO David Bailey sold 19,535 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $17.25, for a total transaction of $336,978.75. Following the completion of the sale, the chief executive officer directly owned 298,020 shares of the company’s stock, valued at approximately $5,140,845. This trade represents a 6.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

OrthoPediatrics Price Performance

Shares of KIDS traded up $0.10 during trading hours on Tuesday, reaching $17.21. 197,133 shares of the stock traded hands, compared to its average volume of 152,452. The company has a market cap of $435.07 million, a P/E ratio of -10.18 and a beta of 1.07. The company has a current ratio of 5.55, a quick ratio of 2.65 and a debt-to-equity ratio of 0.28. The company’s 50-day moving average price is $17.74 and its two-hundred day moving average price is $17.97. OrthoPediatrics Corp. has a 52-week low of $15.28 and a 52-week high of $26.40.

OrthoPediatrics (NASDAQ:KIDS) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.11. OrthoPediatrics had a negative return on equity of 6.70% and a negative net margin of 16.77%.The business had revenue of $61.61 million during the quarter, compared to analyst estimates of $61.27 million. On average, analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

KIDS has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a report on Thursday, January 22nd. Needham & Company LLC boosted their price target on shares of OrthoPediatrics from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Canaccord Genuity Group started coverage on shares of OrthoPediatrics in a report on Wednesday, December 10th. They set a “buy” rating and a $24.00 price objective for the company. TD Cowen upgraded OrthoPediatrics to a “strong-buy” rating in a report on Tuesday, January 27th. Finally, Truist Financial upped their price objective on OrthoPediatrics from $19.00 to $20.00 and gave the stock a “hold” rating in a report on Monday, March 2nd. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.67.

Institutional Trading of OrthoPediatrics

Several hedge funds and other institutional investors have recently bought and sold shares of KIDS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in OrthoPediatrics by 6.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after acquiring an additional 645 shares during the period. Millennium Management LLC boosted its stake in shares of OrthoPediatrics by 55.3% during the first quarter. Millennium Management LLC now owns 656,578 shares of the company’s stock valued at $16,172,000 after purchasing an additional 233,873 shares during the period. Goldman Sachs Group Inc. lifted its holdings in OrthoPediatrics by 112.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 200,439 shares of the company’s stock valued at $4,937,000 after buying an additional 106,041 shares in the last quarter. Jane Street Group LLC purchased a new stake in OrthoPediatrics in the 1st quarter valued at about $389,000. Finally, Los Angeles Capital Management LLC purchased a new stake in OrthoPediatrics in the 2nd quarter valued at about $220,000. Hedge funds and other institutional investors own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.